Investors are always looking for stocks that are poised to beat at earnings season and NGM Biopharmaceuticals, Inc. NGM may be one such company. The firm has earnings coming up pretty soon, and events ...
SOUTH SAN FRANCISCO, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative ...
A phase 2b trial of NGM Biopharmaceuticals’ aldafermin in nonalcoholic steatohepatitis (NASH) has missed its primary endpoint, sending shares in the biotech tumbling. NGM has pulled plans to enter ...
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative ...
After NGM Biopharmaceuticals’ most advanced internal program flunked a mid-stage study last year, the biotech said it would shift its focus to drug candidates covered by a partnership with Merck, ...
If at first you don’t succeed, try again. That’s what NGM Biopharma has done with a previously failed nonalcoholic steatohepatitis candidate in hopes that it could provide some light at the end of a ...
Forbes contributors publish independent expert analyses and insights. I give biotech insiders an edge at Timmerman Report. Feb 23, 2015, 07:00am EST Mar 27, 2015, 03:08pm EDT This article is more than ...
Dr. Yeh will oversee the continued clinical development of NGM Bio's key programs, NGM120 for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis SOUTH SAN ...
SOUTH SAN FRANCISCO, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative ...
NGM boasts a solid pipeline supported by seven clinical programs. Though price targets have changed, analysts still support a 75% upside. With $320 million in cash and $120 million in R&D support, the ...
NGM Biopharmaceuticals confirmed the receipt of the EOI dated Dec. 28 and stated that the company has formed a special committee consisting of disinterested and independent directors to consider the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results